Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 4
2008 1
2009 5
2010 9
2011 7
2012 10
2013 6
2014 8
2015 10
2016 13
2017 9
2018 16
2019 12
2020 7
2021 9
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Cichocki F, Valamehr B, Bjordahl R, Zhang B, Rezner B, Rogers P, Gaidarova S, Moreno S, Tuininga K, Dougherty P, McCullar V, Howard P, Sarhan D, Taras E, Schlums H, Abbot S, Shoemaker D, Bryceson YT, Blazar BR, Wolchko S, Cooley S, Miller JS. Cichocki F, et al. Among authors: cooley s. Cancer Res. 2017 Oct 15;77(20):5664-5675. doi: 10.1158/0008-5472.CAN-17-0799. Epub 2017 Aug 8. Cancer Res. 2017. PMID: 28790065 Free PMC article.
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS. Romee R, et al. Among authors: cooley s. Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20. Blood. 2018. PMID: 29463563 Free PMC article. Clinical Trial.
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. Vallera DA, et al. Among authors: cooley s. Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4. Clin Cancer Res. 2016. PMID: 26847056 Free PMC article.
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Berrien-Elliott MM, et al. Among authors: cooley s. Blood. 2022 Feb 24;139(8):1177-1183. doi: 10.1182/blood.2021011532. Blood. 2022. PMID: 34797911 Clinical Trial.
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Rashidi A, Ali AM, Vij KR, Shanley R, Romee R, Cooley SA, Westervelt P, DiPersio JF, Miller JS, Weisdorf DJ, Ustun C. Rashidi A, et al. Among authors: cooley sa. Am J Hematol. 2017 Sep;92(9):E549-E552. doi: 10.1002/ajh.24804. Epub 2017 Jul 19. Am J Hematol. 2017. PMID: 28568483 Free PMC article. Review. No abstract available.
115 results